KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis
USA - NASDAQ:KRYS - US5011471027 - Common Stock
163.57 USD
+2.96 (+1.84%)
163.57 USD
0 (0%)
Taking everything into account, KRYS scores 6 out of 10 in our fundamental rating. KRYS was compared to 540 industry peers in the Biotechnology industry. KRYS has an excellent financial health rating, but there are some minor concerns on its profitability. KRYS may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, KRYS could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
KRYS had positive earnings in the past year.
KRYS had a positive operating cash flow in the past year.
In multiple years KRYS reported negative net income over the last 5 years.
KRYS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
KRYS's Return On Assets of 12.89% is amongst the best of the industry. KRYS outperforms 94.81% of its industry peers.
KRYS has a Return On Equity of 14.10%. This is amongst the best in the industry. KRYS outperforms 93.89% of its industry peers.
KRYS has a Return On Invested Capital of 12.87%. This is amongst the best in the industry. KRYS outperforms 95.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.89% | ||
| ROE | 14.1% | ||
| ROIC | 12.87% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 40.85%, KRYS belongs to the top of the industry, outperforming 98.15% of the companies in the same industry.
Looking at the Operating Margin, with a value of 42.26%, KRYS belongs to the top of the industry, outperforming 98.89% of the companies in the same industry.
With an excellent Gross Margin value of 93.37%, KRYS belongs to the best of the industry, outperforming 92.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.26% | ||
| PM (TTM) | 40.85% | ||
| GM | 93.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), KRYS is creating some value.
The number of shares outstanding for KRYS has been increased compared to 1 year ago.
Compared to 5 years ago, KRYS has more shares outstanding
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 29.95 indicates that KRYS is not in any danger for bankruptcy at the moment.
The Altman-Z score of KRYS (29.95) is better than 95.56% of its industry peers.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 29.95 |
ROIC/WACC1.34
WACC9.57%
2.3 Liquidity
A Current Ratio of 9.68 indicates that KRYS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.68, KRYS belongs to the top of the industry, outperforming 80.19% of the companies in the same industry.
KRYS has a Quick Ratio of 9.33. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of KRYS (9.33) is better than 79.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.68 | ||
| Quick Ratio | 9.33 |
3. Growth
3.1 Past
KRYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 2794.12%, which is quite impressive.
Looking at the last year, KRYS shows a very strong growth in Revenue. The Revenue has grown by 116.08%.
EPS 1Y (TTM)2794.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%143.4%
Revenue 1Y (TTM)116.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%36.65%
3.2 Future
The Earnings Per Share is expected to grow by 60.52% on average over the next years. This is a very strong growth
Based on estimates for the next years, KRYS will show a very strong growth in Revenue. The Revenue will grow by 32.95% on average per year.
EPS Next Y69.3%
EPS Next 2Y62.51%
EPS Next 3Y54.61%
EPS Next 5Y60.52%
Revenue Next Year32.01%
Revenue Next 2Y39.7%
Revenue Next 3Y41.08%
Revenue Next 5Y32.95%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 33.25, KRYS can be considered very expensive at the moment.
KRYS's Price/Earnings ratio is rather cheap when compared to the industry. KRYS is cheaper than 92.04% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.41. KRYS is valued slightly more expensive when compared to this.
With a Price/Forward Earnings ratio of 20.71, KRYS is valued on the expensive side.
Based on the Price/Forward Earnings ratio, KRYS is valued cheaper than 92.78% of the companies in the same industry.
KRYS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.25 | ||
| Fwd PE | 20.71 |
4.2 Price Multiples
KRYS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. KRYS is cheaper than 93.15% of the companies in the same industry.
94.26% of the companies in the same industry are more expensive than KRYS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.53 | ||
| EV/EBITDA | 23.02 |
4.3 Compensation for Growth
KRYS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of KRYS may justify a higher PE ratio.
A more expensive valuation may be justified as KRYS's earnings are expected to grow with 54.61% in the coming years.
PEG (NY)0.48
PEG (5Y)N/A
EPS Next 2Y62.51%
EPS Next 3Y54.61%
5. Dividend
5.1 Amount
No dividends for KRYS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
163.57
+2.96 (+1.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.38%
Inst Owner Change-0.81%
Ins Owners11.88%
Ins Owner Change-1.19%
Market Cap4.73B
Analysts84.44
Price Target209.94 (28.35%)
Short Float %13.9%
Short Ratio9.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.87%
Min EPS beat(2)-13.89%
Max EPS beat(2)12.14%
EPS beat(4)2
Avg EPS beat(4)6.3%
Min EPS beat(4)-13.89%
Max EPS beat(4)27.68%
EPS beat(8)3
Avg EPS beat(8)-4.07%
EPS beat(12)5
Avg EPS beat(12)-8.82%
EPS beat(16)7
Avg EPS beat(16)-7.79%
Revenue beat(2)1
Avg Revenue beat(2)-3.87%
Min Revenue beat(2)-10.17%
Max Revenue beat(2)2.42%
Revenue beat(4)1
Avg Revenue beat(4)-2.48%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.42%
Revenue beat(8)4
Avg Revenue beat(8)8.28%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.13%
PT rev (3m)0.3%
EPS NQ rev (1m)-2.1%
EPS NQ rev (3m)-23.92%
EPS NY rev (1m)-12.02%
EPS NY rev (3m)-17.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.51%
Revenue NY rev (1m)-4.12%
Revenue NY rev (3m)-6.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.25 | ||
| Fwd PE | 20.71 | ||
| P/S | 13.18 | ||
| P/FCF | 25.53 | ||
| P/OCF | 24.23 | ||
| P/B | 4.55 | ||
| P/tB | 4.55 | ||
| EV/EBITDA | 23.02 |
EPS(TTM)4.92
EY3.01%
EPS(NY)7.9
Fwd EY4.83%
FCF(TTM)6.41
FCFY3.92%
OCF(TTM)6.75
OCFY4.13%
SpS12.41
BVpS35.96
TBVpS35.96
PEG (NY)0.48
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.89% | ||
| ROE | 14.1% | ||
| ROCE | 14.44% | ||
| ROIC | 12.87% | ||
| ROICexc | 36.62% | ||
| ROICexgc | 36.62% | ||
| OM | 42.26% | ||
| PM (TTM) | 40.85% | ||
| GM | 93.37% | ||
| FCFM | 51.63% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 159% | ||
| Cap/Sales | 2.77% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 123.63% | ||
| Profit Quality | 126.39% | ||
| Current Ratio | 9.68 | ||
| Quick Ratio | 9.33 | ||
| Altman-Z | 29.95 |
F-Score8
WACC9.57%
ROIC/WACC1.34
Cap/Depr(3y)534.57%
Cap/Depr(5y)974.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2794.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%143.4%
EPS Next Y69.3%
EPS Next 2Y62.51%
EPS Next 3Y54.61%
EPS Next 5Y60.52%
Revenue 1Y (TTM)116.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%36.65%
Revenue Next Year32.01%
Revenue Next 2Y39.7%
Revenue Next 3Y41.08%
Revenue Next 5Y32.95%
EBIT growth 1Y3666.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year149.9%
EBIT Next 3Y73.68%
EBIT Next 5YN/A
FCF growth 1Y242.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y290.87%
OCF growth 3YN/A
OCF growth 5YN/A